Overview

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

Purpose of this Pilot Study: The investigators want to study the safety, side effects, and benefits of tumor infiltrating lymphocytes (TILs), when they are given with the drug ipilimumab. Ipilimumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

Phase:

N/A

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Collaborators:

Bristol-Myers Squibb
Iovance Biotherapeutics, Inc.
Lion Biotechnologies

Treatments:

Aldesleukin
Antibodies, Monoclonal
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Interleukin-2
Ipilimumab